Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Psycheceutical Bioscience, Inc. Psycheceutical Hosts MAPS Founder and Psychedelic Industry Leader Rick Doblin at Its Drug Development Lab March 29, 2023 From Psycheceutical Bioscience, Inc. Via GlobeNewswire Tickers BWVI Psycheceutical Bioscience, Inc. Announces Observational Research Results for NeuroDirect™ Ketamine Topical Cream in Treating PTSD March 21, 2023 From Psycheceutical Bioscience, Inc. Via GlobeNewswire Tickers BWVI Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD February 15, 2023 From Psycheceutical Bioscience, Inc. Via GlobeNewswire Tickers BWVI Psycheceutical Announces Completion of Pre-IND Meeting with FDA for Topical Ketamine Drug to Treat PTSD February 02, 2023 From Psycheceutical Bioscience, Inc. Via GlobeNewswire Tickers BWVI Psycheceutical Bioscience Provisional Patent Application for Novel Ketamine Topical for the Treatment of PTSD January 26, 2023 From Psycheceutical Bioscience, Inc. Via GlobeNewswire Tickers BWVI Psycheceutical Announces Julian Bailes, M.D. as Board Member and Chief Medical Officer January 10, 2023 From Psycheceutical Bioscience, Inc. Via GlobeNewswire Tickers BWVI Dr. Aric Logsdon Joins Psycheceutical Bioscience, Inc. as Company’s Scientific Director November 29, 2022 From Psycheceutical Bioscience, Inc. Via GlobeNewswire Tickers BWVI Psycheceutical Bioscience, Inc. Announces Medical Advisory Board October 18, 2022 From Psycheceutical Bioscience, Inc. Via GlobeNewswire Tickers BWVI Psycheceutical Bioscience, Inc.'s Zappy Zapolin Added to The Benzinga Psychedelics Advisory Council October 04, 2022 From Psycheceutical Bioscience, Inc. Via GlobeNewswire Tickers BWVI Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.